Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996686 | 1.00 | CTSS (0.64) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL1104212 | 1.00 | CTSS (0.64) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL996688 | 1.00 | CTSS (0.64) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL12040449 | 1.00 | CTSS (0.64) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL996691 | 1.00 | CTSS (0.64) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL10156895 | 0.94 | CTSS (0.62) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL996415 | 0.94 | CTSS (0.62) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL996417 | 0.94 | CTSS (0.62) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL1104181 | 0.94 | CTSS (0.62) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL996416 | 0.94 | CTSS (0.62) | CTSSADRB3ADRA2BADRA2CCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148399-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-03 | — | — | US | disclosed |
| US-8148399-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-03 | — | — | US | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885ADRB3 2852/4885ADRA2B 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.